OCA
TENX icon

Octagon Capital Advisors’s Tenax Therapeutics TENX Stock Holding History

Octagon Capital Advisors’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19
Closed -$54K – 34
2021
Q3 		$54K Buy
+19
New +$49.7K 0.01% 30

Other funds holding TENX

GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return

Octagon Capital Advisors's TENX Position: Q4 2021 in Review

Octagon Capital Advisors sold out of Tenax Therapeutics (TENX) in Q4 2021, closing a stake of 19 shares — an estimated $54K sold.

Octagon Capital Advisors first reported a position in TENX in Q3 2021 and held it in 1 quarter. The position peaked at $54K in Q3 2021. 16 funds tracked by Wall St. Rank hold TENX as of Q4 2021.

  • Octagon Capital Advisors reported no remaining Tenax Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 19 Tenax Therapeutics shares in Q4 2021, an estimated $54K.
  • Octagon Capital Advisors first reported a position in Tenax Therapeutics in Q3 2021 and held it in 1 quarter.
  • Octagon Capital Advisors's Tenax Therapeutics position peaked at $54K in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q4 2021.

Based on Octagon Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.